Result of AGM

CRISM Therapeutics Corporation

27 October 2026

 

27 October 2026

CRISM Therapeutics Corporation

(‘CRISM’, ‘CRISM Therapeutics’ or the ‘Company’)

Result of AGM

CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, is pleased to confirm that at the Company's Annual General Meeting held earlier today, all resolutions were duly passed.

Full details of the resolutions are set out in the Notice of Annual General Meeting dated 2 October 2026, which is available on the Company's website at: https://www.crismtherapeutics.com/investors/documents-circulars/

The votes cast were as follows:

Resolution	Votes for	Votes for %	Votes against	Votes against %	Abstentions
1	22,590,952	99.99%	280	0.01%	3,572
2	22,590,014	99.99%	1,224	0.01%	3,566
3	22,590,221	99.99%	955	0.01%	3,628
4	22,590,227	99.99%	949	0.01%	3,628
5	22,590,215	99.99%	949	0.01%	3,640
6	22,590,227	99.99%	949	0.01%	3,628
7	22,590,909	99.99%	329	0.01%	3,566
8	22,583,989	99.99%	2,139	0.01%	8,676
9	22,570,769	99.99%	2,791	0.01%	21,244

-Ends-

Enquiries:

Company	Nomad and Broker	Financial PR
CRISM Therapeutics Corporation	S.P. Angel Corporate Finance LLP	Burson Buchanan
Andrew Webb, CEO Chris McConville, CSO	David Hignell Vadim Alexandre Adam Cowl	Henry Harrison Topham Jamie Hooper [e-mail]
via Burson Buchanan	[phone]	[phone]

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

CRISM has commenced recruitment at the Company’s first clinical site for its registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma.

For more information please visit: https://www.crismtherapeutics.com/

The Company's LEI is 213800XFW6MKVCHHPW88.

 

END